IPMG Pushes for Access and Availability of Innovative Medicines for Patients
The International Pharmaceutical Manufacturers Group (IPMG), an association of multinational research-based pharmaceutical companies, has officially announced the composition of its Board of Directors for the 2026–2028 period. In this announcement, Evie Yulin (President Director of Merck Indonesia) has been re-elected as Chair of IPMG, supported by George Stylianou (President Director of MSD Indonesia) as Vice Chair.
This leadership duo is expected to strengthen the association’s vision, which represents 25 global pharmaceutical companies in promoting broader healthcare access for patients in Indonesia.
The newly elected IPMG Chair, Evie Yulin, stated that the main focus of her tenure is to bridge the gap in access to innovative medicines. She highlighted data indicating that the availability of innovative medicines in the country remains very limited.
“Currently, only around 9% of innovative medicines are available in Indonesia, and only about 2% can be accessed through public funding. Bridging this gap remains IPMG’s top priority,” said Evie in her official statement on Tuesday (7/4/2026).
Evie emphasised the importance of strong collaboration with the government to ensure more patients receive the benefits of the latest treatments, while supporting the Golden Indonesia 2045 vision. IPMG is committed to promoting a transparent and predictable policy environment.
Several strategic points that the new board will oversee include strengthening the implementation of Health Technology Assessment (HTA), developing sustainable pricing and procurement mechanisms, and aligning registration pathways with patient funding.
In line with this, IPMG Executive Director Ani Rahardjo expressed the association’s readiness to continue playing a constructive role in national policy dialogues.
“We remain open to collaboration to build a more resilient healthcare system and enhance Indonesia’s competitiveness,” added Ani.
In addition to access aspects, IPMG reaffirmed its commitment to maintaining industry ethical standards. The association adopts the Code of Practice from the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) as a guide for interactions with healthcare professionals and medical institutions.
This step is taken to ensure the integrity of the healthcare ecosystem, prevent corrupt practices, and protect the broader public interest.
The 2026–2028 Board of Directors is strengthened by experts in various fields, from regulation and health investment to patient safety. Through this new composition, IPMG aims to affirm the message that health is not merely a cost, but a strategic investment to realise a productive and globally competitive nation.